VCNX News and Press, Vaccinex Inc. From 09/24/19

ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that Maurice Zauderer, PhD, President and Chief Executive ...

Vaccinex (NASDAQ: VCNX ): Q2 GAAP EPS of -$0.77. More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data from CLASSICAL-Lung study at the 2019 American Society of Clinical Oncology (ASCO) Annu...

Vaccinex ( VCNX -1.5% ) announces  full enrollment (n=62) in a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating lead candidate pepinemab (VX15/2503), combined with Pfizer's ( PFE +0.6% ) Bavencio (avelumab), in patients with advanced non-small cell lung cancer (NSCLC). Mor...

63% of evaluable subjects whose tumors had progressed during prior checkpoint inhibitor therapy benefited from treatment with the combination of pepinemab and avelumab Primary completion anticipated in second half of 2019 ROCHESTER, N.Y., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Vaccinex...

Ultra-thinly traded nano cap Vaccinex ( VCNX -9.2% ) is down on average volume, albeit on turnover of only 6K shares, in reaction to its private placement of ~3.4M common shares at $4.08 per share to a group of investors. More news on: Vaccinex, Inc., Healthcare stocks news, Stocks on ...

ROCHESTER, N.Y., July 31, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that the company entered into a stock purchase agreement pr...

The following slide deck was published by Vaccinex, Inc. in conjunction with this Read more ...

ROCHESTER, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that updated interim results of the Phase 1b/2 study of pep...

Vaccinex (NASDAQ: VCNX ): Q1 Revenue of $0.09M (-55.0% Y/Y) Cash and cash equivalents and marketable securities of $11.3M. Press Release More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, ,